JP2014533699A5 - - Google Patents

Download PDF

Info

Publication number
JP2014533699A5
JP2014533699A5 JP2014542546A JP2014542546A JP2014533699A5 JP 2014533699 A5 JP2014533699 A5 JP 2014533699A5 JP 2014542546 A JP2014542546 A JP 2014542546A JP 2014542546 A JP2014542546 A JP 2014542546A JP 2014533699 A5 JP2014533699 A5 JP 2014533699A5
Authority
JP
Japan
Prior art keywords
cancer
independently
substituted
cycloalkyl
heteroarylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014542546A
Other languages
English (en)
Japanese (ja)
Other versions
JP6031527B2 (ja
JP2014533699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/065816 external-priority patent/WO2013078123A1/en
Publication of JP2014533699A publication Critical patent/JP2014533699A/ja
Publication of JP2014533699A5 publication Critical patent/JP2014533699A5/ja
Application granted granted Critical
Publication of JP6031527B2 publication Critical patent/JP6031527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014542546A 2011-11-21 2012-11-19 グルタミナーゼのヘテロ環式阻害剤 Expired - Fee Related JP6031527B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161562266P 2011-11-21 2011-11-21
US61/562,266 2011-11-21
US201261665370P 2012-06-28 2012-06-28
US61/665,370 2012-06-28
US201261727195P 2012-11-16 2012-11-16
US61/727,195 2012-11-16
PCT/US2012/065816 WO2013078123A1 (en) 2011-11-21 2012-11-19 Heterocyclic inhibitors of glutaminase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016178240A Division JP6329226B2 (ja) 2011-11-21 2016-09-13 グルタミナーゼのヘテロ環式阻害剤

Publications (3)

Publication Number Publication Date
JP2014533699A JP2014533699A (ja) 2014-12-15
JP2014533699A5 true JP2014533699A5 (enExample) 2015-12-17
JP6031527B2 JP6031527B2 (ja) 2016-11-24

Family

ID=48470227

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014542546A Expired - Fee Related JP6031527B2 (ja) 2011-11-21 2012-11-19 グルタミナーゼのヘテロ環式阻害剤
JP2016178240A Expired - Fee Related JP6329226B2 (ja) 2011-11-21 2016-09-13 グルタミナーゼのヘテロ環式阻害剤
JP2018080830A Expired - Fee Related JP6577623B2 (ja) 2011-11-21 2018-04-19 グルタミナーゼのヘテロ環式阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016178240A Expired - Fee Related JP6329226B2 (ja) 2011-11-21 2016-09-13 グルタミナーゼのヘテロ環式阻害剤
JP2018080830A Expired - Fee Related JP6577623B2 (ja) 2011-11-21 2018-04-19 グルタミナーゼのヘテロ環式阻害剤

Country Status (26)

Country Link
EP (2) EP2782570B1 (enExample)
JP (3) JP6031527B2 (enExample)
KR (2) KR20190127971A (enExample)
CN (2) CN108785305B (enExample)
AR (1) AR090398A1 (enExample)
AU (1) AU2012340866B2 (enExample)
BR (1) BR112014012129A8 (enExample)
CA (1) CA2856386C (enExample)
CY (1) CY1122707T1 (enExample)
DK (1) DK2782570T3 (enExample)
EA (2) EA026656B1 (enExample)
ES (1) ES2761866T3 (enExample)
HR (1) HRP20192144T1 (enExample)
HU (1) HUE047642T2 (enExample)
IL (2) IL232665A0 (enExample)
LT (1) LT2782570T (enExample)
MX (1) MX362550B (enExample)
PL (1) PL2782570T3 (enExample)
PT (1) PT2782570T (enExample)
RS (1) RS59705B1 (enExample)
SG (2) SG11201402305WA (enExample)
SI (1) SI2782570T1 (enExample)
SM (1) SMT201900738T1 (enExample)
TW (1) TWI585084B (enExample)
WO (1) WO2013078123A1 (enExample)
ZA (2) ZA201404518B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2014043633A1 (en) 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
US10793535B2 (en) * 2012-11-16 2020-10-06 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
EA029531B1 (ru) * 2012-11-21 2018-04-30 Аджиос Фармасьютикалз, Инк. Соединения, ингибирующие глутаминазу, и содержащие эти соединения фармацевтические композиции и их применение
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN105283182A (zh) * 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
US9457016B2 (en) 2013-08-29 2016-10-04 New York University Methods for treating polycystic kidney disease
WO2015061432A1 (en) * 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
KR20220013017A (ko) * 2014-01-06 2022-02-04 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제 저해제
CN103880777B (zh) * 2014-03-06 2015-12-30 陕西科技大学 一种制备双噻二唑二胺的方法
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN106231900B (zh) * 2014-03-21 2019-05-28 阿吉奥斯制药公司 化合物及其使用方法
AU2015254943B2 (en) * 2014-04-30 2019-04-04 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
WO2015192014A1 (en) * 2014-06-13 2015-12-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
JP6619758B2 (ja) * 2014-07-03 2019-12-11 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を処置するためのgls1阻害薬
US10660861B2 (en) 2014-07-09 2020-05-26 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
EA037152B1 (ru) * 2015-03-30 2021-02-11 Калитера Байосайенсиз, Инк. Способ лечения рака
JP6944377B2 (ja) * 2015-04-06 2021-10-06 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼの阻害剤を用いる肺がんの処置
CA2990457C (en) 2015-06-30 2024-07-02 Board Of Regents, University Of Texas System PYRROLIDINYL AND PIPERIDINYL DERIVATIVES AND RELATED PHARMACEUTICAL COMPOSITIONS USEFUL AS GLS1 INHIBITORS
JP6971239B2 (ja) * 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201730188A (zh) * 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
JP6976248B2 (ja) 2015-12-22 2021-12-08 ボード オブ リージェンツ、ザ ユニバーシテイ オブ テキサス システム (r)−1−(4−(6−(2−(4−(3,3−ジフルオロシクロブトキシ)−6−メチルピリジン−2−イル)アセトアミド)ピリダジン−3−イル)−2−フルオロブチル)−n−メチル−1h−1,2,3−トリアゾール−4−カルボキサミドの塩形態および多形体
MX2019002108A (es) 2016-08-25 2019-07-08 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
US10195197B2 (en) 2016-08-25 2019-02-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CN107137401A (zh) * 2017-03-28 2017-09-08 刘纪君 一种治疗产后抑郁症的药物组合物
CN106860460B (zh) * 2017-03-29 2019-04-23 上海市第一人民医院 谷氨酰胺酶抑制剂cb-839在制备治疗雌激素敏感型子宫内膜癌的药物中的应用
US11254666B2 (en) 2017-06-13 2022-02-22 Medshine Discovery Inc. Compound as GLS1 inhibitor
CN111225903B (zh) 2017-10-18 2024-08-16 德州大学系统董事会 谷氨酰胺酶抑制剂疗法
PT3868758T (pt) * 2018-10-16 2023-02-16 Medshine Discovery Inc Derivados de tiadiazole e sua utilização como inibidores gls1 de para o tratamento de cancro
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
KR102649592B1 (ko) * 2021-08-18 2024-03-20 한국화학연구원 신규한 마크로사이클 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN116023375A (zh) * 2021-10-25 2023-04-28 成都苑东生物制药股份有限公司 一种杂环类衍生物、其制备方法及用途
US12337274B2 (en) 2022-07-01 2025-06-24 Saudi Arabian Oil Company Methods for absorption and desorption of carbon dioxide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2296080C (en) 1997-07-29 2005-02-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
WO1999009825A1 (en) 1997-08-29 1999-03-04 Elan Pharmaceuticals, Inc. Method of preventing neuronal death
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な(−)−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP5561702B2 (ja) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Pi3キナーゼ調節剤および使用方法
AU2009228648B2 (en) 2008-03-27 2013-07-11 Grunenthal Gmbh Substituted cyclohexyldiamines
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy

Similar Documents

Publication Publication Date Title
JP2014533699A5 (enExample)
JP2016505526A5 (enExample)
JP2017517548A5 (enExample)
AU2015274361B2 (en) Combination therapy with glutaminase inhibitors
JP2016502544A5 (enExample)
JP2018529780A5 (enExample)
WO2020150417A3 (en) Compounds and compositions for treating conditions associated with sting activity
SA520411325B1 (ar) مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها
EP3277276B1 (en) Methods of administering glutaminase inhibitors
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
JP2019526560A5 (enExample)
JP2020510032A5 (enExample)
KR20180021117A (ko) 아르기나제 활성 억제를 위한 조성물 및 방법
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
JP2010500993A (ja) Hsp90活性を調節するトリアゾール化合物
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
EA200702641A1 (ru) Препараты наночастиц мезилата иматиниба
NZ712479A (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MY161818A (en) Styrenyl derivate compounds for treating ophthalmic diseases and disorders
MX336881B (es) Compuestos heterociclicos triciclicos.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
JP2015522551A5 (enExample)